ABBOTT LABORATORIES

Abbott Laboratories completed its acquisition of Exact Sciences for approximately $20.6 billion in March 2026, significantly expanding its cancer diagnostics portfolio. This strategic move contributed to a 13.0% increase in Q2 2026 net sales to $12.59 billion. However, net earnings for the quarter decreased by 47.9% to $928 million, primarily due to higher interest expenses and amortization costs associated with the acquisition. The acquisition also led to a substantial increase in long-term debt and intangible assets on the balance sheet.

Abbott Laboratories announced strong second-quarter 2026 results, with reported sales growth of 13.0% and adjusted diluted EPS of $1.31. The company raised its full-year 2026 adjusted diluted EPS guidance to $5.45-$5.60, reflecting continued momentum. Key business segments like Medical Devices and Diagnostics showed solid comparable sales growth, while the company also returned $2.1 billion to shareholders and achieved significant product milestones, including a CE Mark for its Libre® Duo sensor.

Abbott Laboratories completed the acquisition of Exact Sciences for approximately $20.6 billion, funded primarily by $20.0 billion in new long-term debt, expanding its cancer diagnostics portfolio. For Q1 2026, net sales increased by 7.8% to $11.16 billion, but net earnings decreased by 18.7% to $1.08 billion, and diluted EPS fell by 19.7% to $0.61, largely due to acquisition-related costs and increased interest expense. The company also noted a $495 million plaintiff verdict in a necrotizing enterocolitis (NEC) lawsuit, the resolution of which could be material to financials.

Abbott Laboratories has amended and restated its By-Laws, effective April 24, 2026. The updated By-Laws detail procedures for annual and special shareholder meetings, including stringent requirements for shareholder nominations of directors and proposals of other business. These amendments aim to ensure proper governance and transparency in shareholder engagement.

Abbott Laboratories announced that the U.S. District Court for the Northern District of Illinois has preliminarily approved a proposed settlement for six consolidated shareholder derivative lawsuits. These lawsuits, previously disclosed in the company's annual reports, were filed against certain current and former directors and officers regarding infant formula. The court's order, issued on April 10, 2026, directs the issuance of notice and sets a final settlement hearing, moving towards a resolution of the litigation.

Abbott Laboratories reported first-quarter 2026 adjusted diluted EPS of $1.15, a 6% increase, with sales growing 7.8% on a reported basis. The company completed its acquisition of Exact Sciences, establishing itself as a leader in oncology diagnostics. Abbott updated its full-year 2026 guidance, projecting comparable sales growth of 6.5% to 7.5% and adjusted diluted EPS of $5.38 to $5.58, which includes a $0.20 dilution from the Exact Sciences acquisition.

Abbott Laboratories has entered into a definitive agreement to acquire Exact Sciences Corporation for $105.00 per share in cash. The acquisition will be completed through a merger of a wholly-owned subsidiary of Abbott with and into Exact Sciences, with Exact Sciences surviving as a subsidiary of Abbott. This acquisition expands Abbott's diagnostics portfolio and presence in the cancer screening market.

Abbott Laboratories has entered into a definitive agreement to acquire Exact Sciences Corporation for $105.00 per share in cash. The acquisition will make Exact Sciences a wholly-owned subsidiary of Abbott and is subject to customary closing conditions, including regulatory approvals and approval by Exact Sciences shareholders.

Abbott Laboratories has entered into a definitive agreement to acquire Exact Sciences Corporation for $105.00 per share in cash. The merger will result in Exact Sciences becoming a wholly-owned subsidiary of Abbott, expanding Abbott's diagnostics portfolio.

Abbott Laboratories announced a temporary suspension of trading in its employee benefit plans, the Abbott Laboratories Stock Retirement Plan (U.S. Plan) and the Abbott Laboratories Stock Retirement Plan (Puerto Rico), due to administrative changes including changing the recordkeeper, trustee, and custodian. During the blackout period, plan participants will be unable to engage in transactions involving their plan assets, including trading Abbott common shares, which could temporarily affect trading volume.